| Pharmaceutical Information |
| Drug Name |
Methsuximide |
| Drug ID |
BADD_D01422 |
| Description |
Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin. |
| Indications and Usage |
For the control of absence (petit mal) seizures that are refractory to other drugs. |
| Marketing Status |
approved |
| ATC Code |
N03AD03 |
| DrugBank ID |
DB05246
|
| KEGG ID |
D00404
|
| MeSH ID |
C100286
|
| PubChem ID |
6476
|
| TTD Drug ID |
D08EOD
|
| NDC Product Code |
0071-0525; 58159-063; 70954-228 |
| UNII |
0G76K8X6C0
|
| Synonyms |
methsuximide | mesuximide | N,2-dimethyl-2-phenylsuccinimide | mesuximid | methsuximide, (+-)-isomer | Celontin | Petinutin | methsuximide, (+)-isomer | methsuximide, (-)-isomer |
|
| Chemical Information |
| Molecular Formula |
C12H13NO2 |
| CAS Registry Number |
77-41-8 |
| SMILES |
CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
